Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

Oppenheimer initiated coverage of Compugen (CGEN) with an Outperform rating and $4 price target. With a sole oncology focus, Compugen is ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

While the Gilead pipeline has promise, the HIV portfolio of drugs has generated the most robust results. It was determined to exit the position as the pipeline timeline has been pushed out.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Livdelzi's approval and strong market potential, combined with Gilead's robust HIV portfolio, position the company for significant revenue growth. Despite competition and debt, Gilead's financial ...

The resulting portfolio is distinctive ... Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the ...